Travere Therapeutics, Inc. (TVTX)

Market Cap	1.50B
Revenue (ttm)	203.45M
Net Income (ttm)	-351.45M
Shares Out	87.03M
EPS (ttm)	-4.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,375,504
Open	17.13
Previous Close	17.40
Day's Range	17.13 - 17.88
52-Week Range	5.12 - 20.33
Beta	0.69
Analysts	Buy
Price Target	23.46 (+36.55%)
Earnings Date	Feb 13, 2025

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurrin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 380
• Stock Exchange: NASDAQ
• Ticker Symbol: TVTX
• Website: https://www.travere.com

Financial Performance

In 2023, Travere Therapeutics's revenue was $145.24 million, an increase of 32.69% compared to the previous year's $109.46 million. Losses were -$111.40 million, -60.00% less than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for TVTX stock is "Buy." The 12-month stock price forecast is $23.46, which is an increase of 36.55% from the latest price.

Price Target

$23.46

(36.55% upside)

Analyst Consensus: Buy